Primary Objective:~Determine the feasibility of three doses of atezolizumab prior to surgery in patients with advanced cutaneous squamous cell carcinoma~Secondary Objectives:~Assess response rates to neoadjuvant atezolizumab Objective response rate following completion of neoadjuvant therapy based on RECIST 1.1 criteria oPathological response rate (major and complete pathological response) in final surgical resection specimen~Assess change in surgical margins or vital structures preserved following neoadjuvant treatment~Assess safety and tolerability of neoadjuvant atezolizumab
The purpose of this research is to evaluate whether the administration of atezolizumab before surgical resection of your tumor is feasible and to evaluate the treatment response, safety, and tolerability of atezolizumab.